Aprea Therapeutics raises $3.1 million in private placement

Aprea Therapeutics Inc. (NASDAQ: APRE) announced it has entered into a securities purchase agreement to raise approximately $3.1 million through a private placement of common stock and warrants.

The clinical-stage biopharmaceutical company will sell 2,623,023 shares of common stock, along with warrants to purchase an additional 2,623,023 shares. The combined offering price for each share and accompanying warrant is $1.165. The warrants carry an exercise price of $1.04 per share and will expire five years after issuance.

The financing involves new and existing healthcare-focused investors as well as company insiders. Maxim Group LLC is serving as the sole placement agent for the transaction, which is expected to close on December 10, 2025.

Aprea stated the net proceeds will fund general corporate purposes and research and development expenses. The company projects the funding will extend its cash runway into the first quarter of 2027.

The securities are being sold in a private placement under Section 4(a)(2) of the Securities Act and have not been registered. Aprea has agreed to file a registration statement with the Securities and Exchange Commission for the resale of the purchased securities.

The Doylestown, Pennsylvania-based company develops treatments targeting cancer cell vulnerabilities. Its lead programs include APR-1051, an oral WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development for solid tumor indications.

You May Also Be Interested In

• Aveanna Healthcare prices secondary offering at $11.75 per share
• QTREX Quantum prices $10 million registered direct offering
• Ensign Group expands credit facility to $800M, extends to 2031